[Pubmed] UPLC-HRMS-based Plasma Metabolomics Study of Thymoma and Thymic Hyperplasia

[RSS-Bot]

Rapid Commun Mass Spectrom. 2023 May 1:e9529. doi: 10.1002/rcm.9529. Online ahead of print.

ABSTRACT

RATIONALE: Thymoma is a rare malignant tumor but it is the most common primary tumor of the anterior mediastinum. The current imaging methods for thymoma screening suffer from false positive rate problem, and thymoma pathogenesis remains elusive. Study of thymoma metabolic characteristics could provide clues for improving the diagnosis and understanding the pathogenesis of thymoma.

METHODS: Metabolic profiling of sera from thymoma and thymic hyperplasia patients was performed using UPLC-HRMS in both positive and negative ionization modes. After pre- and post-processing, the dataset was divided into three age groups and statistical analysis was performed to select differential metabolites of thymoma. For feature identification, experimental MS/MS spectra were matched to those of databases and available chemical standards, and also manually annotated with plausible chemical structures to ensure high identification confidence.

RESULTS: A total of 47 differential metabolites were identified in thymoma. Significant higher levels of histidine, sphinganine 1-phosphate, lactic acid dimer, phenylacetylglutamine, LPC (18:3) and LPC (16:1), and significant lower levels of phenylalanine, indole-3-propionic acid (IPA), hippuric acid and mesobilirubinogen were associated with thymoma. Tryptophan level in thymoma-associated myasthenia gravis (TAMG) was significantly lower than that of the MG (-) group. IPA and hippuric acid abundances exhibited increasing trends from indolent to aggressive thymoma.

CONCLUSION: Our study revealed aberrant aromatic amino acid metabolism and fatty acid oxidation might be associated with thymoma. The identified unique metabolic characteristics of thymoma may provide valuable information for study of the molecular mechanism of thymoma pathogenesis, and improvement of diagnosis and discovery of new therapeutic strategies for thymoma.

PMID:37125446 | DOI:10.1002/rcm.9529


Source: https://pubmed.ncbi.nlm.nih.gov/3712544 ... t6+86293ac